Failed biopharma Talaris Therapeutics has finally reached a strategic review conclusion, delivering a 37% return to us over the last two months. The company has agreed to merge with a late-stage ...
Talaris Therapeutics TALS recently reported the death of a patient in its phase III study evaluating its pipeline candidate, FCR001, in living donor kidney transplant (LDKT) recipients. Post the ...
NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then released ...
Talaris Therapeutics (NASDAQ: TALS) stock should rise 1,000% at the open today. TALS stock should also fall by $15.118. It’s the combination of the two that will lead to the final and new stock price ...
Every investor in Talaris Therapeutics, Inc. (NASDAQ:TALS) should be aware of the most powerful shareholder groups. We can see that private equity firms own the lion's share in the company with 34% ...
Talaris Therapeutics (NASDAQ:TALS) said its shareholders have approved its merger with Tourmaline Bio and a reverse stock split to be conducted just prior to the closing. The combined company will be ...
The American Lupus Society, also known as TALS, merged with the Lupus Foundation of America, Inc. (the Foundation) on July 12, 1997. The Foundation is the successor to The American Lupus Society (TALS ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback